Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study

BMC Neurology
Emilia SbardellaC Pozzilli

Abstract

Neutralizing antibodies (NAbs) against Interferon beta (IFNbeta) are reported to be associated with poor clinical response to therapy in multiple sclerosis (MS) patients. We aimed to quantify the contribution of NAbs to the sub-optimal response of IFNbeta treatment. We studied the prevalence of NAbs in MS patients grouped according to their clinical response to IFNbeta during the treatment period. Patients were classified as: group A, developing >or= 1 relapse after the first 6 months of therapy; group B, exhibiting confirmed disability progression after the first 6 months of therapy, with or without superimposed relapses; group C, presenting a stable disease course during therapy. A cytopathic effect assay tested the presence of NAbs in a cohort of ambulatory MS patients treated with one of the available IFNbeta formulations for at least one year. NAbs positivity was defined as NAbs titre >or= 20 TRU. Seventeen patients (12.1%) were NAbs positive. NAbs positivity correlated with poorer clinical response (p < 0.04). As expected, the prevalence of NAbs was significantly lower in Group C (2.1%) than in Group A (17.0%) and Group B (17.0%). However, in the groups of patients with a poor clinical response (A, B), NAbs positivity was...Continue Reading

References

Jan 1, 1986·Methods in Enzymology·Y Kawade
Jun 13, 2001·Neurology·D K LiUNKNOWN University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group
Sep 29, 2001·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·S E GrossbergJ P Klein
Jan 24, 2002·Neurology·D S GoodinUNKNOWN Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Pra
Nov 27, 2002·Neurology·H PanitchUNKNOWN University of British Columbia MS/MRI Research Group
Jan 15, 2003·Neurology·C PolmanUNKNOWN European Study Group in Interferon Beta-1b in Secondary Progressive MS
Oct 22, 2003·Journal of the Neurological Sciences·Francesca BellomiGuido Antonelli
Oct 22, 2003·Lancet·Per Soelberg SorensenUNKNOWN Danish Multiple Sclerosis Study Group
Mar 12, 2004·Journal of Neurology·Paola PeriniPaolo Gallo
May 22, 2004·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Claudia GneissFlorian Deisenhammer
Oct 9, 2004·Multiple Sclerosis : Clinical and Laboratory Research·C GneissF Deisenhammer
May 13, 2005·Neurology·P Soelberg SorensenUNKNOWN Danish Multiple Sclerosis Study Group
Jul 13, 2005·Neurology·L KapposUNKNOWN European Interferon Beta-1a IM Dose-Comparison Study Investigators
Jul 13, 2005·Neurology·Gordon S FrancisUNKNOWN PRISMS Study Group
Sep 10, 2005·Journal of Neurology·Valentina TomassiniCarlo Pozzilli
Oct 7, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Michel Chofflon
Jan 3, 2006·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·S MalucchiA Bertolotto
Jan 27, 2006·Annals of Neurology·Jordi RíoXavier Montalban
Jun 6, 2007·Multiple Sclerosis : Clinical and Laboratory Research·P S SorensenK Bendtzen
Jul 31, 2007·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·D Hesse, P S Sørensen
May 29, 2008·Multiple Sclerosis : Clinical and Laboratory Research·P S SorensenK Bendtzen
Dec 20, 2008·The Journal of International Medical Research·U RotJ Hillert

❮ Previous
Next ❯

Citations

Feb 11, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·R LanzilloV Bonavita
Sep 30, 2010·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Miranda M C van BeersHuub Schellekens
Jan 1, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Antonio BertolottoSimona Malucchi
Jun 10, 2014·Expert Opinion on Drug Metabolism & Toxicology·Michael D WieseCatherine O'Doherty
Feb 19, 2010·Expert Opinion on Pharmacotherapy·Nancy L KuntzUNKNOWN Network of US Pediatric Multiple Sclerosis Centers
Jan 5, 2016·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Masakazu NakamuraTakashi Yamamura
Nov 6, 2013·Autoimmunity Reviews·Sunil MahurkarCatherine O'Doherty
Dec 3, 2014·Biochemical and Biophysical Research Communications·Chisa KugaShuhei Nishiguchi
Jul 28, 2016·Multiple Sclerosis and Related Disorders·Stefania GalassiCarlo Pozzilli
Sep 4, 2013·Multiple Sclerosis : Clinical and Laboratory Research·Luca ProsperiniCarlo Pozzilli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.